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Abstract
Background: In vivo studies have recently demonstrated that interleukin 21 (IL-21) enhances the
anti-tumor function of T-cells and NK cells in murine tumor models, and the combined use of IL-
21 and IL-15 has resulted in prolonged tumor regression and survival in mice with previously
established tumors. However, the combined anti-tumor effects of IL-21 and low dose IL-2 have not
been studied even though IL-2 has been approved for human use, and, at low dose administration,
stimulates the proliferation of memory T cells, and does not significantly increase antigen-induced
apoptosis or regulatory T cell (Treg) expansion. This study examined whether recombinant IL-21
alone or in combination with low-dose IL-2 could improve the in vivo anti-tumor function of naïve,
tumor-antigen specific CD8+ T cells in a gp10025–33 T cell receptor transgenic pmel murine
melanoma model.
Methods: Congenic C57BL/6 (Ly5.2) mice bearing subcutaneous B16F10 melanoma tumors were
sublethally irradiated to induce lymphopenia. After irradiation naive pmel splenocytes were
adoptively transferred, and mice were immunized with bone marrow-derived dendritic cells pulsed
with human gp10025–33 (hgp10025–33). Seven days after vaccination groups of mice received 5
consecutive days of intraperitoneal administration of IL-2 alone (20 × 103 IU), IL-21 alone (20 µg)
or IL-21 and IL-2. Control animals received no cytokine therapy.
Results: IL-21 alone and IL-2 alone both delayed tumor progression, but only IL-21 significantly
augmented long-term survival (20%) compared to the control group. However, combination
therapy with IL-21 and IL-2 resulted in the highest long-term (>150 days) tumor-free survival
frequency of 46%. Animals that were tumor-free for > 150 days demonstrated tumor-specific
protection after rechallenge with B16F10 melanoma cells. At peak expansion (21 days post
vaccination), the combination of IL-21 plus IL-2 resulted in a 2- to 3-fold higher absolute number
of circulating tumor antigen-specific pmel CD8+ T cells than was stimulated by IL-2 or IL-21 alone.
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Pmel CD8+ T cells were predominantly partitioned into central memory (CD62L+/CD127+) or
effector-memory (CD62L-/CD127+) phenotypes by day 28-post vaccination in IL-21 + IL-2 treated
mice.
Conclusion: These observations support the potential use of IL-21 and low-dose IL-2 therapy in
combination with a tumor-antigen vaccine and lymphopenic conditioning in future cancer clinical
trials to maintain high numbers of anti-tumor memory CD8+ T cells with the potential to sustain
long term tumor regression and survival.
Background
IL-21 has potent immunomodulatory effects on T cells
and NK cells [1]. However, the current understanding of
the effects of IL-21 on the regulation of both antigen-inde-
pendent homeostatic and antigen-stimulated prolifera-
tion and activation of naive and memory CD8+ T cells is
confounded by conflicting data. IL-21 has been reported
both to synergize with IL-15 to increase homeostatic anti-
gen-independent proliferation of naive and memory
CD8+ T cells [2,3], and to inhibit IL-15 induced homeo-
static proliferation of memory T cells [4]. While evidence
suggests IL-21 enhances primary antigen-stimulated T-cell
proliferation and functional activation [3-6], there is disa-
greement over whether this effect occurs during priming
[5], or during the late expansion phase of antigen-specific
proliferation [6]. Recent data suggests IL-21 primarily
increases the frequency and absolute number of in vitro
stimulated antigen-specific CD8+ T cells by enhancing the
rate of proliferation rather than by reducing apoptosis [5].
Alternatively, other studies indicate IL-21 maintains
increased numbers of antigen-stimulated effector and
long-term memory CD8+ T cells by reducing apoptosis
while maintaining a low rate of cell division [6]. These
conflicting data may be attributed to differences in the in
vitro and in vivo models employed in the individual stud-
ies. However, they suggest that much work remains in the
effort to elucidate the mechanism of IL-21 regulation of T-
cell immune responses, including any potential role it
may play in the regulation of T-cell mediated anti-tumor
immunity through the induction of functionally active
tumor-specific effector and memory T cells (Reviewed in
[1]).
In vivo data demonstrate that IL-21 enhances the anti-
tumor function of T-cells and NK cells. Several studies
have shown that genetically engineered IL-21-secreting
murine tumors activate potent NK and CD8+ T cell medi-
ated anti-tumor responses [7-9]. IL-21 was also compared
to IL-2 and IL-15 injected intraperitoneally (IP) subse-
quent to challenge with the ova-expressing E.G7 thy-
moma in either naive C57BL/6 mice, or in mice infused
with OT-1 transgenic CD8+ T cells [6]. In both models, IL-
2 and IL-15 delayed tumor growth, but only IL-21 resulted
in significant prevention of tumor progression and
improved survival beyond 50 days from tumor challenge.
The combination of IL-21 and IL-15 was also adminis-
tered IP subsequent to human gp10025–33 (hgp10025–33)
peptide vaccination of lymphopenic, tumor-bearing
(B16F10 melanoma) C57BL/6 mice [3]. Before vaccina-
tion mice received in vitro stimulated (IVS) pmel trans-
genic (Tg) CD8+ T cells, which have a T-cell receptor
specific for the murine H-2Db restricted gp10025–33 pep-
tide of the B16F10 melanoma associated gp100 protein,
and strongly cross react with hgp10025–33 [10]. The com-
bination of IL-21 + IL-15 resulted in prolonged tumor
regression and survival out to 32 days. Mice treated with
the vaccine plus IL-15 or IL-21 alone all died of tumor
within 32 days of treatment. No data was presented dem-
onstrating long-term survival (>60 days) of mice treated
with IL-21 + IL-15. Notably, IL-2 was not tested in vivo in
combination with IL-21 in this study primarily because
the combination of these two cytokines failed to drive
antigen-independent homeostatic proliferation of murine
CD8+ splenocytes in vitro [3], and the concern that high-
dose IL-2 has been shown to decrease memory CD8+ T-cell
function by inducing regulatory T-cells and increasing
antigen-driven apoptosis [11-14]. However, other data
have demonstrated that the in vitro maintenance of anti-
gen-stimulated murine T cells in low-dose IL-2 resulted in
the proliferative expansion of cells with a memory pheno-
type similar to that induced by IL-15; these cells were
capable of long-term survival in vivo, and potent prolifer-
ative and functional responses after secondary in vivo
challenge [15]. Thus, treatment with IL-21 + low-dose IL-
2 after the adoptive transfer of pmel Tg CD8+ T cells into
mice with established B16 melanoma tumors (pmel Tg/
B16 model) might yield anti-tumor effects comparable to
or greater than those observed with IL-21+IL-15.
The pmel Tg/B16 melanoma model has been employed
repeatedly in recent studies to model immunotherapeutic
strategies for treatment of pre-existing disease. Most of
these experiments have focused on the adoptive transfer
of antigen-educated pmel CD8+ splenocytes stimulated in
vitro with hgp10025–33 peptide and IL-2, and the subse-
quent in vivo expansion of these highly activated cells in
tumor-bearing mice with hgp10025–33  vaccination and
follow-on cytokine therapy [3,16-18]. While this strategy
has resulted in significant tumor regression, little data has
been presented demonstrating long-term curative effectsJournal of Translational Medicine 2006, 4:24 http://www.translational-medicine.com/content/4/1/24
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(≥ 100 days) with IL-2 alone [16,17], IL-15 alone [18], or
the combination of IL-15 and IL-21 [3] – except in mice
with small tumors (≤ 10 mm2) at the time of treatment, or
after the adoptive transfer of very large numbers (107) of
IVS pmel CD8+ T cells [16]. The adoptive transfer of highly
activated IVS T-cells may not produce long-term anti-
tumor curative effects due to functional and proliferative
exhaustion [19-21]. This conclusion is supported by a
series of provocative experiments using the pmel Tg/B16
model in which the adoptive transfer of naive or "early"
IVS-effector pmel CD8+ T cells into lymphopenic tumor-
bearing recipient mice resulted in much more durable
tumor regression following hgp10025–33 vaccination and
IL-2 therapy compared to the poor therapeutic effects
observed using IVS expanded, highly stimulated interme-
diate or late-stage effector T cells [22]. Thus, as described
herein, the adoptive transfer of naïve, tumor antigen-spe-
cific CD8+ T cells in this model prior to vaccine and IL-21
+ low-dose IL-2 therapy may provide a better opportunity
to study methods of generating both effector and long-
term anti-tumor memory T-cell function than can be
achieved with highly activated IVS T cells.
There have been few published studies describing the anti-
tumor effects of recombinant IL-21 in conjunction with
hgp10025–33 vaccination in B16F10 tumor-bearing lym-
phopenic mice receiving naive pmel Tg CD8+ T cells. There
have, to our knowledge, been no reports describing the
potential synergy of IL-21 + low-dose IL-2 in this or other
tumor models. Herein we describe the long-term curative
effect of combined IL-21 + low-dose IL-2 cytokine therapy
in lymphopenic, tumor-bearing C57BL/6 mice infused
with naive pmel splenocytes and vaccinated with the
hgp10025–33 melanoma peptide.
Materials and methods
Mice
Congenic C57BL/6 (Ly5.2) mice (Charles River Laborato-
ries, Inc. NCI-Frederick) bred at the Earle A. Chiles
Research Institute (EACRI) served as recipient mice for
tumor inoculation and pmel Tg CD8+  T-cell adoptive
transfer in all experiments. Pmel Tg mice express a TCR
specific for an H-2Db  epitope (gp10025–33) of the
melanoma-associated gp100 protein on the C57BL/6
(Ly5.1) background [10,16]. Virtually all (>90%) CD8+T
cells in pmel Tg mice were Vβ13+, and were also distin-
guishable by a monoclonal antibody specific for a point
mutation of the CD45 epitope (CD45.2). Pmel Tg mice
were the generous gift of Dr. Nicholas Restifo (Surgery
Branch, NCI-NIH) and were bred at EACRI. Male or
female mice (10–16 weeks) were used in separate experi-
ments. All mice were treated according to the regulations
and guidelines of the Institutional Animal Care and Use
Committee.
Tumor cell lines, tumor inoculation and in vivo 
measurement
The B16 F10 melanoma and 3LL (Lewis Lung) cell lines
were obtained from ATCC. Both cell lines were main-
tained in complete medium consisting of RPMI 1640 sup-
plemented with 10% heat-inactivated fetal bovine serum
(Biofluids, Rockville, MD), 0.03% L-glutamine, 100 µg/
ml streptomycin, 100 µg/ml penicillin, 50 µg/ml gen-
tamicin sulfate and 50 mmol 2-mercaptoethanol. Tumor
was established by injecting mice subcutaneously in the
flank with 2 × 105 B16 F10 melanoma cells in 0.1 ml of
phosphate buffered balanced salt solution (PBS). In
tumor rechallenge experiments mice were injected subcu-
taneously in the opposite flank with 5.0 × 105 B16 F10
melanoma cells or 5.0 × 104 3LL tumor cells in 0.1 ml of
PBS. Tumor growth was monitored three times a week by
measurement of two perpendicular diameters using a dig-
ital caliper. The products of the perpendicular diameters
plotted for multiple animals are presented as the mean
mm2 ± SEM. Mice were sacrificed when tumors exceeded
200 mm2. Survival was analyzed by using Kaplan-Meier
statistics.
Adoptive cell transfer
Splenocytes from pmel transgenic mice were depleted of
erythrocytes with ACK lysing buffer, and 4 × 106 were
adoptively transferred via I.V. injection into C57BL/6
(Ly5.2) mice. Pmel spleen cells contained on average
20%–25% (~1 × 106) naive CD45.2+ CD8+ T cells.
Peptides
The H-2Db-restricted hgp10025–33  peptide, (KVPRN-
QDWL) was used as the CD8+ immunogen [16], and the
I-Ab-restricted epitope of Plasmodium falciparum
(NANPNVDPNANP), hereafter referred to as "NV", was
used as a CD4+directed helper peptide [23,24]in all exper-
iments. The peptides were made by Invitrogen Inc. and
purified by reverse-phase high-performance liquid chro-
matography. Purity of >99% was confirmed by mass spec-
trometry.
Preparation of dendritic cells
Bone marrow-derived murine dendritic cells (DCs) were
generated as described previously [25]. Briefly, cells from
the femur of C57BL/6 mice were grown at 1 × 106 cells/ml
in RPMI 1640 complete medium supplemented with 25
ng/ml of murine GM-CSF (PeproTech, Rocky Hill, NJ).
Fresh medium supplemented with GM-CSF was added on
day 3, and all loosely adherent cells were transferred to
petri dishes on day 6. Three days later, nonadherent and
loosely adherent cells were harvested, washed, and frozen
in 10% DMSO and 90% FCS in liquid nitrogen at 107 cells
per vial. Frozen DCs were thawed and pulsed for 2 hours
at 37°C with hgp10025–33 (1 µg/ml), and 1 µg/ml of the
NV peptide in complete medium. DCs were washed threeJournal of Translational Medicine 2006, 4:24 http://www.translational-medicine.com/content/4/1/24
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times with PBS before injection. DC purity and matura-
tion were confirmed by flow cytometry analysis after
staining with antibodies against MHC class I (H-2Db, H-
2Kb), class II (I-Ab), CD11c, CD40, CD80, CD86. (BD Bio-
sciences PharMingen, San Diego, CA.)
Vaccine and cytokine therapy regimen
After B16F10 tumor cells were injected subcutaneously on
day 0, groups of 5–10 mice per test group were sublethally
irradiated (500 cGy) 7 days later to induce lymphopenia.
All animals were then infused IV with 4 × 106 pmel splen-
ocytes, which equated to the transfer of 8 × 105 - 1 × 106
naive CD45.2+/CD8+ pmel T cells. Immediately after cell
transfer, mice were immunized subcutaneously with 2 ×
106 C57BL/6 DCs pulsed with hgp10025–33 (1 µg/ml) and
NV peptide (1 µg/ml). The hgp10025–33 and NV peptide
pulsed DC immunization was the standard vaccine in all
experiments. Seven days after pmel T cell transfer and vac-
cination, mice received 5 consecutive days (days 14–18
post tumor inoculation) of IP injection of recombinant
human IL-2 at 20 × 103 IU/dose (Chiron Corporation,
Emoryville, CA), murine IL-21 at 20 µg/dose (ZymoGe-
netics Corporation, Seattle, WA), or the combination of
IL-2 and IL-21 at the same dosage used for single cytokine
injections.
Flow cytometry
Except where noted, cell surface staining of peripheral
blood lymphocytes and spleen cells was performed using
BD Biosciences PharMingen (San Diego, CA) reagents.
Single-cell suspensions were incubated with anti-mouse
CD16/32 (eBioscience, San Diego, CA) to block Fc recep-
tors. Cells were then stained with allophycocyanin (APC)
conjugated anti-CD8 and fluorescein isothiocyanate
(FITC)-labeled anti-CD45.2, phycoerythrin (PE) anti-
CD62L and PE-Cy7 anti-CD127 (eBiosciences). Data were
acquired on a FACS Calibur (BD Biosciences, San Jose,
CA.) and analyzed using Cellquest Pro software (version
4.0.1). Peripheral blood and tissue derived-lymphocytes
were analyzed by direct ex vivo interrogation of fresh sam-
ples. The frequency of pmel T cells was determined by
measuring the frequency of total gated CD8+ T cells, which
were also CD45.2+. CD8+ T cells from recipient Ly5.2 mice
could be distinguished from donor pmel CD8+ T-cells
since recipient T cells did not express the CD45.2 point
mutation, and thus were not stained with the anti-CD45.2
antibody. "Flow-Count" fluorospheres (Beckman-Coul-
ter; Miami, Fl.) were added to each sample before event
acquisition to determine the absolute cell count according
to the manufacturer's instructions. A minimum of 8000
"Flow Count" beads were counted for each sample col-
lected. The absolute number of pmel CD8+ T cells per µl
of blood was determined by first calculating the ratio of
beads counted by flow divided by the total number of
beads added to the sample, and multiplying this ratio
times the known volume of the test sample of blood; this
determined the fraction of the total test sample volume
(in µls) analyzed. The total sample volume analyzed (in
µls) was then divided into the total analysis pmel cell
count to give pmel+CD8+ T cells/µl.
Cytokine flow cytometry (CFC) analysis was performed
by stimulating 106 spleen cells suspended in 250 ul of
complete medium in a microtiter well (96 well plate) with
hgp10025–33 peptide (1 ug/ml). Splenocytes were cultured
with antigen and brefeldin A (10 ug/ml) for 5 hours at
37°C. Cells were washed twice in PBS and incubated with
anti-mouse CD16/32 (FcR-blocking) monoclonal anti-
body (eBiosciences). Cells were then stained with APC-
conjugated CD8 and FITC-labeled CD45.2 (eBiosciences)
antibodies for 30 minutes at 4°C, washed 2× in PBS, and
fixed and permeablized with 100 ul Cytofix/Cytoperm™
buffer/well (BD Biosciences Pharmingen) for15 minutes
at room temperature. Cells were washed 2× in Per-
mWash™ buffer (BD Biosciences Pharmingen) and resus-
pended in 100 ul of PermWash™ buffer. PE-conjugated
anti-IL-2, IFNγ or TNFγ specific antibodies (BD Bio-
sciences Pharmingen) were added at optimal dilution and
incubated for one hour at 4°C; PE-conjugated isotype
controls were used to determine non-specific cytoplasmic
background staining. Cells were washed 2× with PBS and
analyzed by flow cytometry. Cytokine positive cell fre-
quencies were determined for pre-gated CD8+/
CD45.2+pmel T cells.
Statistical analysis
Phenotype data in this study were analyzed using repeated
measures analysis of variance (ANOVA), analysis of covar-
iance (ANCOVA), linear hierarchical mixed-effects regres-
sion models, nonparametric (distribution free) tumor
growth analyses, and simple and advanced graphical tech-
niques [26-28]. Animal survival data were analyzed with
standard log-rank statistics and Kaplan-Meier plots. Pair
wise a posteriori comparisons among treatment conditions
were performed with standard post hoc tests (i.e. Tukey's
test). Interpretations of tumor growth results from follow-
up tests were consistent with those obtained from global
analyses. Hence, for simplicity we report probability (p)
values obtained from follow-up nonparametric Wilcoxon
tests at specific time points. All tests were two-sided; prob-
ability values less than 0.05 were considered significant.
Results
Combined IL-21 + IL-2 therapy significantly enhanced 
anti-tumor immunity
Seven days after subcutaneous injection of 2 × 105 B16F10
melanoma cells C57BL/6 mice were sublethally irradi-
ated, infused with naive pmel splenocytes and vaccinated
with hgp10025–33 pulsed DCs. Seven days later therapy
was initiated with 5 daily IP injections (days 14–18 postJournal of Translational Medicine 2006, 4:24 http://www.translational-medicine.com/content/4/1/24
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tumor inoculation) of IL-2 alone, IL-21 alone or both
cytokines. The optimal dose of IL-21 (20 µg/dose) was
established previously [6]; and the optimal IL-2 dose (20
× 103 IU/injection) was established by titration (data not
shown). Figure 1 shows the cumulative mean tumor size
from three separate experiments during the first four
weeks following tumor inoculation (≥ 15 mice/group).
On day 14, just prior to cytokine administration, the
mean tumor size for all vaccinated mice (N = 73) was 26
mm2 (± 2.4 mm). Thus, all vaccinated mice had estab-
lished disease prior to cytokine therapy. Global analysis
showed that each therapy, including the vaccine alone,
reduced the rate of tumor growth compared to the irradi-
ation only control. By day 21, vaccination combined with
IL-21 + IL-2 treatment inhibited tumor growth signifi-
cantly better than vaccination alone (p = 0.0013) and vac-
cination combined with IL-2 (p = 0.0044) or with IL-21 (p
= 0.044). By day 28, vaccination combined with IL-21+ IL-
2 again inhibited tumor growth significantly better than
vaccination alone (p < 0.0001) and vaccination combined
with IL-2 (p = 0.0006) or with IL-21 (p = 0.0033). By day
30, vaccination combined with IL-21 + IL-2 similarly
inhibited tumor growth significantly better than vaccina-
tion alone (P < 0.0001), but produced higher statistically
significant inhibition than vaccination combined with IL-
2 (p = 0.0002) or with IL-21 (p = 0.0024) when compared
to day 28. Mice in the irradiation only (lymphopenic)
control group exhibited rapid tumor growth; the mean
B16F10 melanoma tumor growth in hgp10025–33 vaccinated and cytokine treated lymphopenic mice Figure 1
B16F10 melanoma tumor growth in hgp10025–33 vaccinated and cytokine treated lymphopenic mice. Tumor size is presented as 
the mean (mm2) ± SEM of the cumulative analysis of replicate mice (≥ 15) for each test group from 3 separate experiments. 
Cytokines were administered for 5 consecutive days beginning on day 14 when the average tumor size for vaccinated mice 
from all test groups in 3 experiments was 26 mm2 ± 2.4 mm (N = 73 mice). By day 30 IL-21 + low-dose IL-2 treated mice 
showed significant inhibition of tumor growth compared to the vaccine control (p < 0.0001), or compared to vaccinated mice 
treated with IL-2 (p = 0.0002) or IL-21 only (p = 0.0024).
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tumor size for all animals reached > 200 mm2 30 days
after tumor inoculation. Similarly, unvaccinated tumor-
bearing control mice which were irradiated and treated
with IL-21 or IL-21 + IL-2 only had comparable rapid
tumor growth (data not shown). Mice treated with IL-21
+ IL-2 after vaccination were the only animals that experi-
enced no significant increase in tumor size (Figure 1).
IL-21 + IL-2 improved long-term tumor-free survival
Having shown that treatment with IL-21+ low-dose IL-2
significantly delayed early tumor growth, we compared
the effects of the three different cytokine regimens on
long-term tumor regression and overall survival beyond
30 days. Figure 2 shows individual tumor growth curves
and long-term survival for all mice in each test group col-
lected from three separate experiments. The large majority
of tumor-bearing mice that received sublethal irradiation
only (Figure 2A) had progressing tumors ≥ 200 mm2 by
day 28. Control animals that received sublethal irradia-
tion and the hgp10025–33 vaccine exhibited a short delay
in tumor progression, but >80% of the mice had tumors ≥
200 mm2 by day 35. There were no long-term survivors
among mice whose treatment did not include a cytokine
(Figure 2A, B). Approximately half of the mice treated
with low dose IL-2 demonstrated a modest delay of tumor
growth to ≥ 200 mm2 until approximately day 42, and
there was one long-term survivor (Figure 2C). IL-21 treat-
ment resulted in an even longer delay (Figure 2D) in
tumor progression, with 50% of animals reaching day 49
with tumors < 200 mm2, and 3/15 mice from the three
experiments survived long-term. Mice treated with both
IL-21 and IL-2 exhibited the best anti-tumor response.
Among 24 mice from three separate experiments approxi-
mately 63% survived to day 49 with tumors < 200 mm2,
and 46% (11/24) remained tumor free 63 days after
tumor inoculation (Figure 2E). The cumulative long-term
survival of mice from all groups from three experiments
followed out to 150 days post tumor inoculation showed
that IL-21 + IL-2 treated mice had significantly better sur-
vival (46%) compared to all other groups (Figure 2F).
Combined therapy with IL-21 and IL-2 resulted in
improved survival compared to vaccination only (p <<
Rate of tumor growth and long-term survival in tumor-bearing mice after hgp10025–33 vaccination and cytokine therapy Figure 2
Rate of tumor growth and long-term survival in tumor-bearing mice after hgp10025–33 vaccination and cytokine therapy. Cumu-
lative analysis of tumor growth rates are depicted for all replicate mice from 3 separate experiments in which mice were irra-
diated only (A), irradiated and vaccinated (B), or irradiated, vaccinated and treated with IL-2 (C), IL-21 (D), or IL-21 + IL-2 (E). 
Both IL-21 and IL-21 + IL-2 therapy delayed tumor progression in >50% of treated mice until day 42 while tumors in control 
and IL-2 treated mice all progressed more rapidly. IL-21 + IL-2 treated mice had a significant survival advantage (46%) over IL-
21 (p = 0.035), or IL-2 (p << 0.0001) treated mice; and IL-21 therapy alone (20% survival) was significantly better than the vac-
cine only (p = 0.03) (F).
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0.0001), vaccination plus IL-2 (p << 0.0001), or vaccina-
tion plus IL-21 (p = 0.035). The IL-21 only effect was sig-
nificantly better than the vaccine only control (p = 0.030),
but there was no significant difference between the long-
term survival response to IL-21 alone and IL-2 alone (p =
0.80). All surviving mice in the IL-21 + IL-2 test group
were tumor-free at day 150-post tumor inoculation.
Tumor-Specific Protective Immunity in Long-Term 
Survivor Mice
To determine whether long-term tumor-specific protec-
tive immunity developed after treatment with IL-21 + IL-
2, mice surviving tumor free for 150 days were subse-
quently rechallenged subcutaneously with 5 × 105 B16F10
tumor cells or 5 × 104 3LL tumor cells. Tumor size was
monitored three times per week out to 39 days (Figure 3).
All 4 mice injected with control 3LL cells developed tumor
(mean size >150 mm2) by day 32, while all 5 mice chal-
lenged with B16F10 were tumor-free to day 39, and
remained so for another 150 days (data not shown). Addi-
tional control groups included naive congenic C57BL/6
mice inoculated with B16F10 (5 mice) or 3LL (5 mice)
tumor cells. The mean tumor size for both tumors in naive
control mice reached 200 mm2 before day 25. Thus, the
regimen of adoptive cell transfer with lymphopenic con-
ditioning and tumor antigen vaccination followed by IL-
21 + IL-2 therapy was curative in mice with established
tumors, and produced a long-term tumor-specific mem-
ory response capable of protecting against a secondary
challenge with the original tumor.
IL-21 + IL-2 therapy induced high numbers of circulating 
pmel CD8+ T cells
Representative data from one of three experiments dem-
onstrated that IL-21 + IL-2 therapy in the pmel Tg/B16F10
model induces higher absolute numbers of circulating
Tumor-specific protective immunity in long-term survivor mice Figure 3
Tumor-specific protective immunity in long-term survivor mice. IL-21 + IL-2 treated mice that survived disease free for 150 
days were rechallenged with B16F10 (5 × 105) or 3LL(5 × 104) tumor cells. All 3LL challenged mice (4/4) exhibited mean tumor 
growth to ≥ 200 mm2 by day 32; all B16F10 challenged mice (5/5) were protected. Naïve mice challenged with the same 
B16F10 (5/5) or 3LL (5/5) tumor cells had rapid mean tumor growth to ≥ 200 mm2 by day 25.
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pmel CD8+ T cells than either IL-2 or IL-21 therapy alone
(Figure 4). Pooled blood from 5–10 mice in each cytokine
group and the vaccine only control were stained for CD8/
CD127/CD62L/CD45.2 expression, and the absolute
number of circulating pmel CD8+ T cells was determined
using counting beads as described. Analysis of variance
(ANOVA) was performed on cell counts made at weekly
intervals from 7–28 days post vaccine administration
from pooled samples for each group; there was a signifi-
cant difference between test groups (p = 0.029). A follow-
up (post hoc) Tukey test showed that the absolute number
of circulating pmel CD8+ T cells in peripheral blood was
significantly higher after combined cytokine therapy than
following IL-2 (p < 0.05), or IL-21 (p < 0.05) therapy
alone at 14, 21, and 28 days after vaccination. The expan-
sion of circulating pmel cells appeared to peak at day 21
and go through a contraction phase from day 21 to day 28
in mice treated with IL-21+ IL-2, and for mice in the vac-
cine only control group. Cell numbers remained relatively
constant from day 14–28 for mice treated with IL-21 or IL-
2 alone.
Cell surface phenotype of pmel CD8+ T cells from 
cytokine-treated mice
Detailed pmel CD8+ T cell subset analysis (CD8/CD127/
CD62L/CD45.2) was performed on pooled peripheral
blood samples from mice used in the experiment
described in Figure 4. Recent reports have identified
CD127 (IL-7α receptor) expression as an important
descriptor for long-lived memory T cells which may arise
Quantitation of absolute numbers of pmel CD8+ T cells Figure 4
Quantitation of absolute numbers of pmel CD8+ T cells. Pooled blood from mice in the vaccine control and all three cytokine 
experimental groups (≥ 5 mice/group) was analyzed by flow cytometry to determine the absolute number of circulating pmel-1 
CD8+ T cells/µL of blood. Vaccinated mice treated with IL-21+ IL-2 had the highest total pmel CD8+ cell numbers at all time 
points. Data are shown from a representative experiment and show that IL-21 + IL-2 resulted in significantly higher circulating 
pmel CD8+ T cell numbers than was produced by IL-2 (p = 0.05), or IL-21 (p = 0.05) alone.
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early after in vivo priming [29-34]. These studies also indi-
cated that CD62L and CD127 staining partitioned anti-
gen-specific cells into two distinct memory T cell subsets
which, by functional criteria, were similar to central mem-
ory T cells (Tcm) with a CD62L+/CD127+ phenotype, and
effector memory (Tem) cells with a CD62L-/CD127+ phe-
notype [32,33]. Effector T cells (Te) were CD62L-/CD127-
and were characterized by poor proliferation response,
immediate effector function, and high levels of antigen-
induced apoptosis [33]. Figure 5 shows dot plots of
CD127 versus CD62L staining of pre-gated CD8+/
CD45.2+ peripheral blood pmel T cells obtained on days
14, 21 and 28 from each cytokine therapy group and vac-
cine only control mice. The frequency of circulating pmel
CD8+ T cells with a Tcm phenotype on day 14 was no dif-
ferent in IL-2, and IL-21 + IL-2 treated mice or in the vac-
cine controls. Only IL-21 treated mice showed a small
increase in Tcm frequency, which was 15% higher than
that produced in control mice. Tem frequencies following
treatment with IL-2 or with IL-21 + IL-2 were 30% and
63% higher respectively than in control mice. The fre-
quencies of both Tcm and Tem pmel CD8+  T cells
decreased on day 21 for all experimental groups com-
pared to day 14 values. The day 21 frequency of Tem pmel
CD8+ T cells (CD62L-/CD127+) was similar for all test
groups except IL-21 + IL-2, which maintained approxi-
mately a 70% higher Tem percentage. The frequencies of
Tcm (CD62L+/CD127+) on day 21 indicated IL-2 sus-
tained a slightly higher percentage than the control
(22%); IL-21 stimulation resulted in a 54% higher fre-
quency of Tcm CD8+ T cells compared to the control, and
IL-21 + IL-2 treated mice maintained a Tcm frequency
35% higher than the control. By day 28 the control and IL-
2 induced Tcm frequencies were equal to each other but
CD27 vs CD62L 2 parameter phenotype analysis of pmel CD8+ T cells Figure 5
CD27 vs CD62L 2 parameter phenotype analysis of pmel CD8+ T cells. Lymphocytes from pooled blood (5–10 mice/group) in 
a representative experiment were analyzed for CD127 and CD62L staining. Flow cytometry phenotype analysis of pmel CD8+ 
T cells on days 14, 21 and 28 post vaccination indicated higher frequencies of antigen specific Tcm (CD62L+/CD127+) were 
induced at all time points by IL-21 alone compared to the control and IL-2 stimulated PBMCs; IL-21 + IL-2 stimulated compara-
bly high Tcm frequencies on days 21 and 28. IL-21+IL-2 stimulated the highest frequency of pmel CD8+ Tem (CD62L-/CD127+) 
at all time points.
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higher than on day 21, while the IL-21 effect (38%
increase) and the IL-21 + IL-2 effect (25% increase) on
Tcm expression were both similarly elevated compared to
the control and IL-2 induced percentages. Combined IL-
21 and low-dose IL-2 therapy sustained the circulating
Tem frequency at a level that was 2-fold higher than the
control group or the effect induced by IL-2 alone or IL-21
alone. The cell density plots for IL-21+IL-2 on all three
days also suggested an overall higher absolute number of
circulating Tcm and Tem CD8+/CD45.2+ T cells than was
induced by any other treatment. Generally, lower percent-
ages of circulating effector cells (CD62L-/CD127-) were
present at day 21 and day 28 for IL-21 and IL-21+IL-2
treated mice compared to both IL-2 treated animals and
control mice. The upper left quadrant of each 2-parameter
histogram contained CD62L+/CD127- T cells, and their
Quantitation of absolute numbers of Tem and Tcm CD8+ T cells Figure 6
Quantitation of absolute numbers of Tem and Tcm CD8+ T cells. PBMCs were examined by flow cytometry to determine the 
absolute number of Tem (CD62L-/CD127+) pmel CD8+ T cells (A), and Tcm (CD62L+/CD127+) pmel CD8+ T cells (B) on days 
14, 21, and 28 after vaccination and cytokine treatment. IL-21 + IL-2 supported the highest level of circulating Tem cells on all 
three days compared to all other experimental groups (p = 0.011), and stimulated the greatest increase of Tcm cells on days 21 
and 28 (p = 0.029). Data was collected from pooled blood from ≥ 5 mice in each test group.
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frequency was generally lower in the IL-21 and IL-21+IL-2
treated animals. Presently there is no correlated functional
data to determine the lineage relationship of this popula-
tion to Tcm or Tem T cells or their functional properties.
Overall the data in Figure 5 suggest IL-21+IL-2 induced
higher frequencies of Tem cells compared to IL-2 or IL-21
alone on all three days; and by the early contraction phase
of the pmel CD8+ T cell response (day 28) IL-21 and IL-21
+ low-dose IL-2 induced equally higher percentages of
tumor-specific Tcm cells than were stimulated in the con-
trol or IL-2 treated mice.
IL-21+ IL-2 induced proliferation of Tem and Tcm pmel 
CD8+ T cells
The frequencies of Tcm and Tem T cells on days 14, 21 and
28 (Figure 5), and the total number of circulating pmel
cells determined for each group (Figure 4) were subse-
quently used to calculate the absolute number of Tem
(Figure 6A) and Tcm (Figure 6B) pmel CD8+ T cells for
each experimental group. Tem numbers on each day were
significantly higher for IL-21+ IL-2 treated mice than for
all other groups (p = 0.011) as determined by ANCOVA,
and declined from day 14 to day 28 (Figure 6A). By con-
trast, the absolute number of Tcm cells for all groups was
equally low at day 14 and increased incrementally for
each group over time (Figure 6B). IL-21 + IL-2 induced
Tcm cell numbers increased at a significantly higher rate
compared to all other test groups (p = 0.029) as deter-
mined by ANCOVA. Thus, IL-21+ IL-2 treatment main-
tained Tem absolute numbers at all time points that were
2- to 4-fold greater than those produced by the vaccine
control or by IL-2 or IL-21 therapy alone. Similarly, Tcm
absolute numbers induced by IL-21+ IL-2 were 2- to 4-
fold higher than those stimulated in any other test group
by day 28. Recent data have demonstrated that the adop-
tive transfer of pmel CD8+ Tcm (characterized as CD62L+/
CCR7+), or "early effector" T cells (CD62Ldim/CD127+/
CCR7+) produced a potent anti-tumor response subse-
quent to tumor-antigen hgp10025–33  vaccination and
high-dose IL-2 therapy in the pmel Tg/B16 therapeutic
model [22,35]. The data in Figure 6B suggest IL-21+ low-
dose IL-2 in vivo therapy promotes the long-term mainte-
nance of CD8+  T cells with a similar Tcm (CD62L+/
CD127+) or "early effector" – like phenotype (CD62Ldim/-
/CD127+).
Functional phenotype of CD8+ T cells from IL-21 + IL-2 
treated tumor regressor mice
By day 42 previously regressing tumors in a subset of IL-
21 + IL-2 treated mice began to grow again, reaching a
mean tumor size of 25–50 mm2. All tumors of this size on
day 42–49 continued to progress to ≥ 200 mm2 by day 63,
whereupon the mice were sacrificed. However, approxi-
mately 50% of all IL-21+ IL-2 treated mice in three exper-
iments did not exhibit tumor growth, and by day 42–49
manifested complete regression of the tumor. These ani-
mals remained tumor free out to >150 days. Day 42 splen-
ocytes from two "progressor", and from two "regressor"
mice treated with IL-21 + IL-2 were pooled separately, and
were stimulated in vitro with hgp10025–33; cells were then
Cytokine flow cytometry analysis of the functional phenotype of pmel CD8+ splenocytes from IL-21 + IL-2 treated mice Figure 7
Cytokine flow cytometry analysis of the functional phenotype of pmel CD8+ splenocytes from IL-21 + IL-2 treated mice. Spleen 
cells were pooled from 2 mice with progressing tumors (≥ 50 mm2) and from 2 mice with regressing tumors (<10 mm2) 42 
days after vaccination. Cytokine flow cytometry analysis shows the absolute number of pmel CD8+ T cells per 106 splenocytes 
(A), and the frequency of pmel CD8+ cells (B) that are positive for IL-2, IFNγ, and TNFγ production. Data show mice with 
regressing tumors had 4.7-fold, 4.8-fold and 2.5-fold more IL-2+, IFN-γ+, and TNF-α+ pmel CD8+ T cells respectively, and 
higher frequencies of Tc1 cytokine+ cells than progressor mice.
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analyzed for IFNγ, IL-2 and TNF-α production using a
standard five-hour CFC assay. After IVS cells were fixed,
permeablized, and stained with CD8, CD45.2 and
cytokine-specific antibodies. Spleens from regressor mice
had more IFNγ, IL-2 and TNF-α positive CD8+/CD45.2+
pmel T cells than spleens from progressor animals (Figure
7A). Regressor mice had 4.7-fold, 4.8-fold, and 2.5-fold
more IL-2+, IFNγ+ and TNF-α+ pmel CD8+ T cells, respec-
tively, than progressor mice with rapidly growing tumors.
The data in Figure 7A indicates that tumor regression in
mice receiving IL-21+ IL-2 therapy was associated with an
increase in the absolute number of pmel CD8+ T cells pro-
ducing Tc1 cytokines compared to the numbers found in
mice with growing tumors. The presence of higher num-
bers of Tc1 cytokine+ CD8+ T cells in regressor compared
to progressor mice was attributable to both a 2-fold
greater absolute number of pmel CD8+ T cells in regressor
mice than were measured in progressor animals (data not
shown) and to higher frequencies of pmel CD8+ T cells
which were positive for Tc1 cytokines in regressor mice at
42 days (Figure 7B).
Discussion and conclusions
We report for the first time the anti-tumor effects of a
treatment strategy that combines lymphopenic condition-
ing, adoptive transfer of naive antigen-specific CD8+ T
cells, tumor antigen-specific vaccination, and cytokine
treatment with IL-21 + low-dose IL-2. Using a well estab-
lished murine model of pre-existing disease, the pmel Tg/
B16 model, our results show that combined IL-21 + low-
dose IL-2 therapy delayed B16F10 melanoma growth in
the majority of mice, and resulted in a significant increase
in tumor-free survival (46%) out to ≥ 150 days compared
to mice treated with IL-21 or IL-2 alone. Surviving mice
exhibited tumor-specific protective immunity since they
resisted B16F10 rechallenge but succumbed to the unre-
lated 3LL tumor. These data are in contrast to other studies
in the pmel Tg/B16 model, which employed the adoptive
transfer of highly activated IVS pmel CD8+ T cells (stimu-
lated with hgp10025–33 peptide and IL-2 or IL-15) rather
than naive pmel T cells [3,17,18]. After lymphopenic con-
ditioning and T-cell transfer to tumor-bearing mice, ther-
apy was administered in these studies using different
combinations of hgp10025–33 vaccination and cytokine
treatment. Thus, Lou et al [17] vaccinated with hgp10025–
33 peptide-pulsed DCs, and administered high-dose IL-2
(1.2 × 106 IU/day) for three days beginning the day of vac-
cination. Klebanoff, et al [18] vaccinated with a recom-
binant fowl pox virus encoding hgp10025–33 (rFPhgp100)
after adoptive transfer of IVS pmel CD8+ T cells grown in
IL-2 or in IL-15 cultures. Follow-on cytokine therapy con-
sisted of high-dose IL-2 (1.2 × 106 IU/day) for three days.
In the only published study using IL-21 in the pmel Tg/
B16 model Zeng and coworkers [3] also vaccinated with
rFPhgp10025–33 following adoptive transfer of IL-2 cul-
tured pmel T cells, and animals were treated over three
days with IL-15 (20 µg/day), IL-21 (20 µg/day), or both
cytokines at the same doses. None of these treatment strat-
egies resulted in long-term inhibition of tumor growth
beyond 30–35 days after treatment unless very large num-
bers (4–6 × 106) of IVS pmel CD8+ T cells were adoptively
transferred [17]. Furthermore, in contrast to our results,
none of these studies presented data describing long-term
tumor-free survival ≥ 150 days with any combination of
transferred T cells, vaccine administration and cytokine
therapy. Another group compared the ability of IL-2, IL-15
or IL-21 to augment anti-tumor immunity in C57BL/6
mice challenged with the OVA-expressing E.G7 thymoma
[6]. Cytokine therapy was initiated 48 hours after tumor
inoculation – well before the establishment of vascular-
ized tumors, and was administered every other day for
two weeks thereafter. In this model IL-21 (20 µg/day) did
result in prolonged tumor-free survival out to 100 days in
approximately 25–30% of treated mice. Neither low-dose
IL-2 (2 × 103 IU and 20 × 103 IU/day) nor IL-15 (5 µg and
50  µg/day) produced a survival frequency that was as
high. All animals that survived beyond 100 days were pro-
tected from rechallenge with E.G7 tumor cells. Impor-
tantly, this report also showed that the 2-week cytokine
administration could begin as late as day 12 following
tumor inoculation and still produce a therapeutic
response [6]. This study also demonstrated the ability of
IL-21 to augment immunity to the OVA-expressing E.G7
tumor in the absence of previously antigen-educated
CD8+ T cells. However, the experimental design did not
test the anti-tumor effects of IL-21 in a model of estab-
lished bulky disease such as the pmel Tg/B16 system, in
which the cognate tumor antigen is a relatively weak self-
tumor antigen rather than a strongly immunogenic for-
eign protein. To date only the combined therapeutic
effects of IL-21+ low-dose IL-2 reported here have resulted
in long-term survival of tumor-free mice in the pmel Tg/
B16 model. As noted, in most of the previous studies
using the pmel Tg/B16 melanoma model very high doses
(1.2 × 106 IU/day) of IL-2 were used in combination with
the adoptive transfer of large numbers (up to 107) of
highly activated IVS pmel CD8+ T cells [16-18] However,
treatment was initiated after very large, bulky (50–100
mm2) tumors were established. By contrast, cytokine ther-
apy was initiated in our experiments when vascularized
tumors were smaller (26 mm2). Long-term survival using
our current IL-21 + IL-2 therapeutic model may decrease
with larger established tumors; experiments designed to
test and optimize IL-21 +low-dose IL-2 therapy in mice
with larger vascularized tumors are ongoing.
The H-2Db-restricted NV peptide was used in all experi-
ments as a putative CD4 "helper" antigen source [23,24]
However, our recent experiments suggest NV peptide vac-
cination produces only a modest increase in circulatingJournal of Translational Medicine 2006, 4:24 http://www.translational-medicine.com/content/4/1/24
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pmel CD8+  T cell numbers over that produced by
hgp10025–33 alone (unpublished data – H.M. Hu, EACRI).
CD4 helper T cell function in our DC-based vaccine sys-
tem may have been provided by fetal calf serum (FCS)
proteins/peptides associated with the DCs in the vaccine
– both DCs and the B16F10 melanoma cells used in the
tumor inoculum were cultured in medium containing
FCS. The potential for FCS antigen-induced CD4 T cell
activation is also suggested by other hgp10025–33-pulsed
DC vaccine studies in the pmel Tg/B16 model in which
anti-tumor therapeutic effect was achieved in the absence
of any known source of CD4-specific antigen [17].
There is limited information on IL-21-mediated changes
in the cell surface and functional phenotype of CD8+ T-
cells associated with tumor immunity. In this report, we
show that IL-21 alone and IL-21+ low-dose IL-2 increased
the in vivo frequency of Tcm T cells as defined by concom-
itant CD62L+/CD127+ staining[29], compared to the vac-
cine only control or to cells from IL-2-treated mice (Figure
5). IL-21 + IL-2 treatment also sustained the highest per-
centage of Tem (CD62L-/CD127+) pmel CD8+ T cells [29]
compared to any other test group. This observation corre-
lated with the result that IL-21+ IL-2 therapy also pro-
duced the highest absolute number of circulating pmel
CD8+ T cells during the beginning (day 14), peak (day 21)
and end (day 28) of the hgp10025–33 induced expansion
of pmel CD8+ T cells (Figure 4). As a consequence, IL-21 +
IL-2 therapy produced the highest absolute number of cir-
culating pmel CD8+ Tem cells at each time point of the
expansion and early contraction phases of the anti-
hgp10025–33 immune response, and also resulted in the
highest absolute number of Tcm T cells in the peripheral
blood (Figure 6). Although Tem absolute numbers
decreased from day 14 to day 28, and Tcm numbers
increased over this same period the data do not indicate if
this is attributable in anyway to innate differences in IL-21
+ IL-2 induced Tem vs Tcm proliferation. Future in vitro
and in vivo studies will examine the relative proliferative
potential of cognate antigen-driven purified populations
of pmel CD8+ Tcm and Tem cells. Notably, the tumor-spe-
cific protective memory response observed in long-term
survivor mice was also associated with high frequencies of
Tcm in the spleen and lymph nodes. Polychromatic (8
color) flow cytometry analysis of pmel CD8+ splenocytes
from IL-21 + IL-2 treated long-term survivor mice (> 150
days) indicated approximately 10%–12% of all CD8+ T
cells in the spleen and lymph nodes were pmel CD8+ T
cells, and 43% and 70% of these T cells in the lymph
nodes and spleen respectively expressed a Tcm phenotype
(CD62L+/CD127+/CD27+/CD28+)(unpublished data).
Recent data have demonstrated that enriched pmel CD8+
Tcm T cells conferred a potent in vivo anti-tumor recall
response upon adoptive transfer – leading to the eradica-
tion of large established tumors in the pmel Tg/B16
model [35]. Thus, as described herein, IL-21 + IL-2 ther-
apy favored the in vivo expansion and maintenance of
such tumor antigen-specific Tcm T cells from naive pmel
CD8+ T cell precursors which were capable of providing
long-term protective immunity. Preliminary phenotype
analysis of IL-21 + low-dose IL-2 and hgp10025–33 IVS
pmel splenocytes similarly indicates the combination of
both cytokines results in the proliferation of pmel Tg
CD8+  T cells with a Tcm (CD62L+/CD127+/CD27+/
CD28+) phenotype (unpublished data – EACRI). This fur-
ther suggests that IL-21 + low-dose IL-2 might be effective
in supporting the cognate antigen-driven in vitro expan-
sion of rare self-tumor antigen Tcm CD8+ T cells from
autologous PBMCs – perhaps in concert with procedures
to remove tumor antigen-specific regulatory T cell effects.
In addition to increasing tumor-antigen directed expan-
sion and maintenance of Tcm CD8+ T cells, data presented
here demonstrates that IL-21 + IL-2 therapy also stimu-
lated the expression of anti-tumor memory CD8+ T cells
with a Tc1 cytokine functional phenotype in mice with
regressing tumors. By day 42 post-tumor inoculation IL-
21 + IL-2 treated tumor-regressor mice had much higher
absolute numbers of IL-2+, IFNγ+ and TNF-α+ pmel CD8+
splenocytes than IL-21 + IL-2 treated tumor-progressor
mice with rapidly growing tumors (Figure 7). The relative
absence of CD8+ splenocytes with a Tc1 cytokine func-
tional phenotype in tumor progressor mice may be attrib-
utable in part to a simple lack of sustained B16F10 tumor
antigen stimulation. Previous published data from our
institute using the pmel Tg/B16 model has demonstrated
loss of MHC class I and gp100 expression in a high per-
centage of tumors in experimental animals with progres-
sive disease due to immunoediting[36]. Overall our data
suggest that IL-21 + low-dose IL-2-mediated tumor regres-
sion and long-term survival was associated with elevated
absolute numbers of tumor antigen-specific Tem and Tcm
CD8+ T cells with a Tc1 functional phenotype.
IL-21 + low-dose IL-2 induction of increased in vivo
expression of Tc1 cytokine+ Tcm and Tem CD8+ T cells is a
central observation for any putative mechanistic explana-
tion of the anti-tumor therapeutic synergy produced using
both cytokines. This observation examined in the context
of recent studies describing the broad inhibitory effects of
IL-21 on B lymphocytes, NK cells and DCs (Reviewed in
[37]) suggests a possible mechanism for the IL-21+ low-
dose IL-2 induced expansion of Tcm CD8+ T cells similar
to what may occur during the late contraction phase of an
ongoing immune response. Thus, CD4 T cell (Th2)-
derived IL-21[38] inhibits anti-IgM and IL-4-mediated B
cell proliferation [2] and enhances apoptosis of activated
B cells [39,40], inhibits DC maturation and the ability of
DCs to prime T cells [41,42]; and increases NK maturation
and cytolytic function while inhibiting NK proliferation
[43]. Similarly, while IL-21 has generally been describedJournal of Translational Medicine 2006, 4:24 http://www.translational-medicine.com/content/4/1/24
Page 14 of 16
(page number not for citation purposes)
as an inducer of antigen stimulated IFNγ and CTL func-
tion in CD8+ T cells [4,8,44,45], our unpublished data in
both murine and human in vitro experiments indicate IL-
21 alone does not drive high levels of cognate antigen
stimulated CTL proliferation. In vivo data presented here
suggest that IL-21 works best in concert with low-dose IL-
2 to support both optimal anti-tumor effector CTL func-
tion and expansion of CD8+ memory T cells. Paradoxi-
cally, IL-21 + low-dose IL-2 treatment produced
unexpectedly low frequencies of circulating effector pmel
CD8+ T cells (Figure 4) – perhaps due to cell trafficking to
the primary tumor and sites of metastatic disease. Ongo-
ing experiments are directed at the in situ analysis of the
phenotype, cell number, and functional properties of
tumor invasive pmel CD8+ T cells in IL-21 + low dose IL-
2 treated mice. Such studies should shed light on whether
combined cytokine therapy induces trafficking of
increased numbers of antigen-specific cytolytic CD8+ T
cells to the tumor site. Taken together, these observations
suggest a dual role for IL-21 in dampening ongoing innate
and adaptive immune responses (as might occur during
the contraction phase of antigen-specific immunity),
while concomitantly augmenting the expansion of anti-
gen-driven long-term memory T cells. Recently published
data demonstrate IL-21 treated cultures of antigen-stimu-
lated cells produce CD8+ T cells with increased TCR bind-
ing affinity [5]. Other data show the IL-21 receptor (IL-
21R) is upregulated upon TCR engagement [46,47]. Thus,
Th2-derived IL-21 may "rescue" memory T cells by block-
ing further antigen-driven effector T cell differentiation
through presently unknown mechanisms, while simulta-
neously increasing antigen binding affinity. The resulting
increase in binding of low-levels of residual antigen
(present during the contraction phase) could increase IL-
21R expression and up-regulate increased IL-21 binding
to memory T cells – thus further skewing the shift to mem-
ory T cells. Memory CD8+ T cells in turn express amplified
levels of CD122 [48], which may facilitate increased high
affinity IL-2R formation if other IL-2R chains (CD25 and
CD132) are available, and potentially increase binding of
the low levels of IL-2 which may be present during immu-
nological contraction. The combination of the "arrested"
Tcm memory phenotype (maintained by IL-21), and low
dose IL-2-induced proliferation of these cells could result
in increased Tcm cell numbers. Thus, IL-21 + low-dose IL-
2 therapy may favor the enhanced expansion of long-term
memory (Tcm) CD8+ T cells through augmented memory
T cell "rescue" and expansion mechanisms similar to
those which may normally be present during the late con-
traction phase of an ongoing immune response. This con-
cept is supported by the results of our study and other
reports [6,8], which suggest IL-21 induced tumor immu-
nity is most effective when IL-21 is administered several
days (4–12 days) after initial tumor-antigen activation of
T cells. The late acting anti-tumor effects of IL-21, and, in
our study, IL-21 + IL-2 therapy suggests IL-21 may be act-
ing directly on tumor antigen educated CD8+ T cells rather
than modulating early APC and/or T cell function associ-
ated with primary tumor antigen stimulation. Preliminary
in vitro studies with purified naïve and hgp10025–33 stim-
ulated pmel CD8+ T cells support this conclusion (data
not shown).
In summary, the results of this study suggest that IL-21 +
low-dose IL-2 cytokine therapy may "rescue" and aug-
ment proliferation of tumor antigen-specific memory
CD8+ T cells, and thus provide an important new strategic
component for effective cancer immunotherapy. The
combined use of both cytokines may be most effective in
the context of lymphopenic conditioning, tumor antigen-
specific vaccination, and the adoptive transfer of autolo-
gous tumor-specific Tcm or "early" effector T cells. Ongo-
ing work at our institute continues to focus on developing
procedures for the IL-21 + low-dose IL-2-directed in vivo
and in vitro expansion and maintenance of such Tcm and
"early" effector subpopulations from small numbers of
normally tolerized autologous self-tumor antigen-specific
precursors.
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